Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

Emotional processing in Parkinson's disease and anxiety: an EEG study of visual affective word processing

A general problem in the design of an EEG-BCI system is the poor quality and low robustness of the extracted features, affecting overall performance. However, BCI systems that are applicable in real-time and outside clinical settings require high performance. Therefore, we have to improve the current methods for feature extraction. In this work, we investigated EEG source reconstruction techniques to enhance the extracted features based on a linearly constrained minimum variance (LCMV) beamformer. Beamformers allow for easy incorporation of anatomical data and are applicable in real-time. A 32-channel EEG-BCI system was designed for a two-class motor imagery (MI) paradigm. We optimized a synchronous system for two untrained subjects and investigated two aspects. First, we investigated the effect of using beamformers calculated on the basis of three different head models: a template 3-layered boundary element method (BEM) head model, a 3-layered personalized BEM head model and a personalized 5-layered finite difference method (FDM) head model including white and gray matter, CSF, scalp and skull tissue. Second, we investigated the influence of how the regions of interest, areas of expected MI activity, were constructed. On the one hand, they were chosen around electrodes C3 and C4, as hand MI activity theoretically is expected here. On the other hand, they were constructed based on the actual activated regions identified by an fMRI scan. Subsequently, an asynchronous system was derived for one of the subjects and an optimal balance between speed and accuracy was found. Lastly, a real-time application was made. These systems were evaluated by their accuracy, defined as the percentage of correct left and right classifications. From the real-time application, the information transfer rate (ITR) was also determined. An accuracy of 86.60 ± 4.40% was achieved for subject 1 and 78.71 ± 0.73% for subject 2. This gives an average accuracy of 82.66 ± 2.57%. We found that the use of a personalized FDM model improved the accuracy of the system, on average 24.22% with respect to the template BEM model and on average 5.15% with respect to the personalized BEM model. Including fMRI spatial priors did not improve accuracy. Personal fine- tuning largely resolved the robustness problems arising due to the differences in head geometry and neurophysiology between subjects. A real-time average accuracy of 64.26% was reached and the maximum ITR was 6.71 bits/min. We conclude that beamformers calculated with a personalized FDM model have great potential to ameliorate feature extraction and, as a consequence, to improve the performance of real-time BCI systems

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

International audienceIn 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field